Oxygen Bonded Directly At The 6-position Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 552/501)
-
Patent number: 11390644Abstract: A method of forming a probe, wherein the method includes converting cholenic acid into a compound with a terminal alkyne group, wherein the converting the cholenic acid comprises using a sequence, wherein the sequence comprises synthesizing a THP-protection group, LiAlH4 reduction, Dess-Martin oxidation, and Seyferth-Gilbert-Bestmann homologation. The method additionally includes forming A-Chol by removing the THP-protection. Further, the method includes forming PhA-Chol from the compound with the terminal alkyne group via a palladiumcatalyzed Sonogashira reaction. Additionally, the method includes forming PhDY Chol from the compound with the terminal alkyne group via a coppercatalyzed Cadiot-Chodkiewicz reaction.Type: GrantFiled: November 20, 2018Date of Patent: July 19, 2022Assignee: Purdue Research FoundationInventors: Mingji Dai, Ji-Xin Cheng
-
Patent number: 10131687Abstract: A method of forming a probe, wherein the method includes converting cholenic acid into a compound with a terminal alkyne group, wherein the converting the cholenic acid comprises using a sequence, wherein the sequence comprises synthesizing a THP-protection group, LiAlH4 reduction, Dess-Martin oxidation, and Seyferth-Gilbert-Bestmann homologation. The method additionally includes forming A-Chol by removing the THP-protection. Further, the method includes forming PhA-Chol from the compound with the terminal alkyne group via a palladiumcatalyzed Sonogashira reaction. Additionally, the method includes forming PhDY-Chol from the compound with the terminal alkyne group via a coppercatalyzed Cadiot-Chodkiewicz reaction.Type: GrantFiled: June 27, 2017Date of Patent: November 20, 2018Assignee: Purdue Research FoundationInventor: Mingji Dai
-
Patent number: 6969708Abstract: The invention pertains to a process for the preparation of a high purity composition of (7?, 17?)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one. The process provides for a composition with less than 0.5% of (7?, 17?)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one. This composition can be used as a source for the preparation of stable pharmaceutical dosage units.Type: GrantFiled: October 11, 1999Date of Patent: November 29, 2005Assignee: Akzo Nobel N.V.Inventors: Peter H. G. M. Kirchholtes, Gerard A. J. M. T. Sas
-
Patent number: 6521767Abstract: In a process for the suspension hydrogenation of an anthraquinone compound or a mixture of two or more thereof in a reactor in which there are present the working solution in which at least one catalyst is suspended and, in addition, a hydrogen-containing gas phase, the working solution and the gas phase are, in the reactor, passed at least partly through a fitting having openings or channels whose hydraulic diameter is from 0.5 to 20 mm, preferably from 1 to 10 mm, particularly preferably from 1 to 3 mm.Type: GrantFiled: August 28, 2000Date of Patent: February 18, 2003Assignee: BASF AktiengesellschaftInventors: Arnd Böttcher, Jochem Henkelmann, Franz Josef Bröcker, Gerd Kaibel, Heinz Rütter
-
Patent number: 6011023Abstract: Methods and compositions for preventing and treating neovascularization with steroids is disclosed.Type: GrantFiled: August 27, 1997Date of Patent: January 4, 2000Assignee: Alcon Laboratories, Inc.Inventors: Abbot F. Clark, Raymond E. Conrow
-
Patent number: 5686435Abstract: The invention pertains to vitamin D amide derivatives of formula (I). These novel 1.alpha.-hydroxy vitamin D derivatives and their 20-epi analogues comprise compounds of formula (I) and corresponding 5,6-trans isomers, where Y represents an alkylene or alkenylene group containing up to four carbon atoms; R.sup.1 and R.sup.2 independently represent a hydrogen atom or a lower alkyl or cycloalkyl group, or R.sup.1 R.sup.2 N-- represents a heterocyclic group; and R.sup.3 and R.sup.4 independently represent a hydrogen atom or an O-protecting group. Active compounds, in which R.sup.3 and R.sup.4 are hydrogen atoms or metabolically labile O-protecting groups exhibit potent cell modulating effect, but minimal effect on calcium metabolism.Type: GrantFiled: December 7, 1995Date of Patent: November 11, 1997Assignee: Research Institute for Medicine and ChemistryInventors: Robert Henry Hesse, Gaddam Subba Reddy, Sundara Katugam Srinivasasetty Setty
-
Patent number: 5494905Abstract: The invention pertains to vitamin D amide derivatives of formula (I). These novel 1.alpha.-hydroxy vitamin D derivatives and their 20-epi analogues comprise compounds of formula (I) and corresponding 5,6-trans isomers, where Y represents an alkylene or alkenylene group containing up to four carbon atoms; R.sup.1 and R.sup.2 independently represent a hydrogen atom or a lower alkyl or cycloalkyl group, or R.sup.1 R.sup.2 N-- represents a heterocyclic group; and R.sup.3 and R.sup.4 independently represent a hydrogen atom or an 0-protecting group. Active compounds, in which R.sup.3 and R.sup.4 are hydrogen atoms or metabolically labile 0-protecting groups exhibit potent cell modulating effect, but minimal effect on calcium metabolism.Type: GrantFiled: May 31, 1994Date of Patent: February 27, 1996Assignee: Research Institute for Medicine and ChemistryInventors: Robert H. Hesse, Gaddam S. Reddy, Sundara K. S. Setty
-
Patent number: 4975537Abstract: Disclosed are .DELTA..sup.9(11) -steroids of the formula ##STR1## which have been found to be angiostatic and therefore are useful in the control of embryogenesis, inflammatory conditions, tumor growth as well as other abnormalities.Type: GrantFiled: May 15, 1989Date of Patent: December 4, 1990Assignee: The Upjohn CompanyInventors: Paul A. Aristoff, Harvey I. Skulnick, Wendell Wierenga